Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

STAT: PhRMA CEO Says FDA Review Process Is ‘Gold Standard and Should Remain So’

Boston, MA, February 22, 2017 — Rebecca Robbins reports on STAT+ that Stephen Ubl, the President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), yesterday came out strongly in favor of a rigorous Food and Drug Administration (FDA).

Ubl’s remarks come as the Trump administration weighs potential candidates to lead the agency who have suggested they would radically change how it vets new drugs.

Asked by STAT about the notion that the FDA should no longer evaluate drugs for effectiveness, Ubl was unambiguous: “We believe that the FDA review process is the gold standard and should remain so.”

Robbins reports that Mr. Ubl wouldn’t comment on specific candidates rumored to be under consideration to lead the FDA, which reportedly include Jim O’Neill, the Silicon Valley libertarian, and Fairleigh Dickinson’s Dr. Joseph Gulfo, who has called for scaling back the requirements for approval.

Ubl’s comments about the FDA — and other biopharmaceutical-related topics — came during a press conference with journalists after he delivered brief remarks to a small crowd gathered in Boston for a morning of panel discussions with scientists and drug industry executives.

The gathering was put on by the events division of The Atlantic magazine and sponsored by PhRMA.

Tuesday’s event was the first stop on PhRMA’s barnstorming tour to bolster the industry’s image as part of the “Go Boldly” campaign.

For the full story, click here.

Follow Rebecca Robbins on Twitter @rebeccadrobbins.

Follow STAT — which reports from the frontiers of health and medicine — on Twitter @statnews.